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Chemotherapy, one of the mainstays of cancer treatment today, was pioneered at Yale dur-
ing World War II. last year, two Yale surgeons, Drs. John fenn and Robert Udelsman,
sought to unearth the mystery surrounding the discovery of chemotherapy and its first use
at Yale. The first chemotherapy patient is known only as JD in the literature, and without a
name, date of birth, or medical record number, a search for his record seemed futile. How-
ever, persistence coupled with sheer fortune led them to JD’s chart, where they found in-
formation that differed from previous accounts. The riveting personal story of JD, an
immigrant patient with lymphosarcoma, was revealed for the first time by Drs. fenn and
Udelsman on January 19, 2011, at a special Surgical Grand Rounds celebrating the bicen-
tennial of Yale School of Medicine. 
IntroductIon
Cancer is the second most common
cause of death in the United States, ac-
counting for nearly 1 out of every 4 deaths
[1].  In  2010,  it  was  estimated  that
1,529,560 Americans would be diagnosed
with cancer and 569,490 would succumb to
the disease at an overall cost to the health
care system of $263.8 billion [1]. The life-
time risk of being diagnosed with cancer is
41 percent, and the five-year survival rate
for all cancers diagnosed between 1999 and
2005 was 68 percent, a substantial increase
from the 50 percent reported in 1975-1977
[2]. This improvement in survival can be
attributed to earlier diagnosis and advance-
ments in treatment.
One of the mainstays of cancer treat-
ment is chemotherapy, which is increas-
ingly being used by today’s oncologists [3].
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Hodgkin lymphoma; mechlorethamineHistorically, the origin of chemotherapy has
been shrouded in secrecy due to the circum-
stances surrounding its discovery. Reports
of  its  first  use  at  a Yale  hospital  during
World War II are scattered within the litera-
ture [4-6]. However, reference to the first pa-
tient treated with chemotherapy was based
on personal recollection rather than medical
facts, as the chart had been misplaced. Lost
within this record was the personal and med-
ical  history  of  JD,  a  man  whose  illness
sparked the birth of chemotherapy. The case
of JD remained a mystery for more than 60
years, until Yale School of Medicine physi-
cians Dr. John Fenn, clinical professor of
surgery, and Dr. Robert Udelsman, profes-
sor and chair of the Department of Surgery,
became curious and sought to uncover his
story. Without a name, date of birth, medical
record number or precise date of treatment,
the search for JD’s record seemed futile.
However, in May 2010, persistence coupled
with sheer fortune led them to an off-site
storage facility that contained JD’s medical
chart. To their surprise, the facts contained
therein differed from those that had been
previously reported, including inaccuracies
in the personal history of JD, the circum-
stances surrounding his treatment, and his
clinical course. 
JD’s story was revealed for the first
time at a Yale Bicentennial Lecture on Jan-
uary 19, 2011, when Drs. Fenn and Udels-
man  gave  a  captivating  account  of  how
chemotherapy was discovered and its first
use at Yale. As Yale School of Medicine cel-
ebrates its 200th anniversary, we reflect on
its pivotal contributions to the field of med-
icine. The discovery of chemotherapy at
Yale serves as the quintessential model for
scientific innovation: diligent basic scien-
tists  collaborating  with  translational  re-
searchers  and  dedicated  clinicians  to
develop a novel therapy and offer hope to
terminal patients. 
Jd’s hIstorY
JD was born in Poland in 1894 and im-
migrated to the United States at the age of
18. He lived in Connecticut and worked in a
ball bearing factory until he became ill in
August 1940. What began as tonsillar en-
largement and right submandibular pain rap-
idly progressed to multiple enlarging masses
that were biopsied and found to be lym-
phosarcoma. Before long, they occupied the
entire right side of his neck, and he could
barely open his mouth. He was referred to
the Yale Medical Center in February 1941
for X-ray therapy and admitted to what is
now Yale-New Haven Hospital. He under-
went external beam radiation for 16 consec-
utive days with considerable reduction in
tumor size and amelioration of his symp-
toms. However, his improvement was short
lived, and by June 1941, he required addi-
tional surgery to remove cervical tumors. He
underwent several more cycles of radiation
to reduce the size of the tumors, but by the
end of the year they became unresponsive
and had spread to the axilla. By August
1942, two years after the initial onset of
symptoms, he suffered from respiratory dis-
tress, dysphagia, and weight loss, and his
prognosis appeared hopeless.
The treatment of lymphosarcoma at the
time was surgical resection and radiation
therapy, which had been shown to improve
symptoms and prolong life [7]. However, re-
lapse and death were common, and cases
arising from the tonsils were reported to be
most malignant [7]. Now refractory to radi-
ation therapy and having exhausted all sur-
gical  options,  JD’s  doctors  turned  to  an
experimental therapy whose origins can be
traced back to World War I. JD’s physicians
believed that nitrogen mustard, a related
compound of the poison gases responsible
for  1,205,655  non-fatal  casualties  and
91,198 deaths during the war, was his only
chance for survival [8]. The leukopenic ef-
fect of mustard gas on blood and bone mar-
row  was  first  reported  by  Dr.  Edward
Krumbhaar in 1919 after treating exposed
soldiers at a hospital in France [9]. He no-
ticed a peculiar change in the hematological
profile in these soldiers: an initial increase
in erythrocyte and leukocyte count, followed
by a profound decrease in circulating leuko-
cytes attributed to “exhaustion of the leuko-
cyte forming centers” in the bone marrow.
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Office of Scientific Research and Develop-
ment (OSRD†), an agency of the War De-
partment,  to  fund  research  investigating
potential antidotes [10]. 
A contract was signed with Yale School
of Medicine to fund a research team led by
Dr. Alfred Gilman, a pharmacologist, and Dr.
Louis Goodman, a physician and pharmacol-
ogist [6]. They used a rabbit model to evalu-
ate  the  toxicity  of  nitrogen  mustard  and
observed a similar decrease in the number of
circulating lymphocytes and granulocytes. It
occurred to them that this might have poten-
tial as a treatment for patients with lymphoid
malignancies, and they initiated trials on mice
with transplanted lymphomas in collabora-
tion  with  anatomist  and  colleague  Dr.
Thomas Dougherty. The results were prom-
ising, and a marked decrease in tumor size
was observed in the mice receiving treatment,
corresponding to a prolongation of life. The
researchers  presented  these  results  to  Dr.
Gustaf Lindskog, then an assistant professor
of surgery at Yale, as a potential treatment for
humans with refractory lymphoma. Having
exhausted all other treatment modalities, the
medical team offered experimental nitrogen
mustard chemotherapy to JD. Despite having
already  experienced  numerous  relapses,
physical suffering, and emotional anguish, JD
maintained the will to survive and agreed to
undergo experimental chemotherapy. Con-
currently,  the  Chemical  Warfare  Service
began controversial research testing of mus-
tard gas on human subjects [11] and started
investigating other chemical agents as coun-
termeasures should they become necessary.
As a result of censoring by the War Depart-
ment, nowhere in JD’s record do the words
“nitrogen mustard” appear; rather, the sub-
stance was referred to as “a lymphocidal” or
“substance X.” Although both human trials
preceded the Nuremberg Code, Belmont Re-
port, and establishment of Institutional Re-
view Boards (IRBs), a distinction must be
made between the therapeutic use of nitrogen
mustard on JD and its experimental use on
military volunteers.
At 10 a.m. on August 27, 1942, JD re-
ceived  his  first  dose  of  chemotherapy
recorded as 0.1 mg/kg of synthetic lym-
phocidal chemical. This dosage was based
on toxicology studies performed in rabbits.
He  received  10  daily  intravenous  injec-
tions,  with  symptomatic  improvement
noted after the fifth treatment. Biopsy fol-
lowing completion of the treatment course
remarkably revealed no tumor tissue, and
he was able to eat and move his head with-
out difficulty. However, by the following
week,  his  white  blood  cell  count  and
platelet count began to decrease, resulting
in gingival bleeding and requiring blood
transfusions. One week later, he was noted
to have considerable sputum production
with recurrence of petechiae, necessitating
an additional transfusion. By day 49, his tu-
mors had recurred, and chemotherapy was
resumed with a 3-day course of “lympho-
cidin.” The response was short-lived, and
he was administered another 6-day course
of substance “X.” Unfortunately, he began
experiencing intraoral bleeding and multi-
ple peripheral hematomas and died peace-
fully  on  December  1,  1942  (day  96).
Autopsy revealed erosion and hemorrhage
of the buccal mucosa, emaciation, and ex-
treme aplasia of the bone marrow with re-
placement by fat.
conclusIon
The riveting account of JD shared by
Drs. Fenn and Udelsman on the first use of
chemotherapy at Yale illustrates a monu-
mental event in modern medicine. The mul-
tidisciplinary team of Yale pharmacologists
and physicians was able to characterize the
mechanism of action of nitrogen mustard
and  translate  their  findings  from  animal
studies to the first human trial as a treatment
for refractory lymphosarcoma. In adminis-
tering the first dose of nitrogen mustard,
they provided proof of concept that intra-
venous chemotherapy resulted in tumor re-
gression, but that resistance occurred after
multiple dosages. They also observed the
profound bone marrow suppression result-
ing from chemotherapy use, which puts pa-
tients at a high risk of infection and death.
This crucial discovery founded the field of
171 Christakis: Birth of chemotherapy at Yalemedical oncology and would not have been
possible without the courage of JD. The full
details of JD’s life, medical history, and
treatment course, as well as a historical ac-
count of the origin of chemotherapy, have
been published by Drs. Fenn and Udelsman
in the Journal of the American College of
Surgeons [12].
references
1. American Cancer Society. Cancer Facts &
Figures 2010 [Internet]. Atlanta: American
Cancer  Society;  2010.  Available  from:
http://www.cancer.org/acs/groups/con-
tent/@nho/documents/document/acspc-
024113.pdf.
2. National Cancer Institute: SEER Cancer Statis-
tics Review, 1975-2007 [Internet]. Altekruse
SF,  Kosary  CL,  Krapcho  M,  Neyman  N,
Aminou R, Waldron W, et al., editors. Available
from: http://seer.cancer.gov/csr/1975_2007/.
3. National  Cancer  Institute:  Cancer  Trends
Progress Report ― 2009/2010 Update. Avail-
able from: http://progressreport.cancer.gov.
4. Goodman LS, Wintrobe MM, et al. Nitrogen
mustard therapy; use of methyl-bis (beta-
chloroethyl) amine hydrochloride and tris
(beta-chloroethyl) amine hydrochloride for
Hodgkin's disease, lymphosarcoma, leukemia
and certain allied and miscellaneous disor-
ders. J Am Med Assoc. 1946;132:126-32.
5. Gilman A, Philips FS. The biological actions
and  therapeutic  applications  of  the  B-
chloroethyl  amines  and  sulfides.  Science.
1946;103:409-15.
6. Gilman A. The initial clinical trial of nitro-
gen mustard. Am J Surg. 1963;105:574-8.
7. Holding AF. The Results of the Treatment of
Lymphosarcoma by Means of X-Rays and
Other Methods. Ann Surg. 1917;65:686-92.
8. Reminick G. Nightmare in Bari: The World
War II Liberty Ship Poison Gas Disaster and
Coverup. Palo Alto, CA: The Glencannon
Press; 2001.
9. Krumbhaar EB. Role of the blood and the
bone marrow in certain forms of gas poison-
ing. J Am Med Assoc. 1919;72:39-41.
10. Hirsch  J.  An  anniversary  for  cancer
chemotherapy. JAMA. 2006;296:1518-20.
11. Pearson GS. Veterans at Risk: The Health Ef-
fects of Mustard Gas and Lewisite. Pechura
CM, Rall DP, editors. Nature. 1993;365:218.
12. Fenn JE, Udelsman R. First use of intra-
venous chemotherapy cancer treatment: rec-
tifying  the  record.  J  Am  Coll  Surg.
2011;212:413-7.
172 Christakis: Birth of chemotherapy at Yale